Objective: Anal cancer rates are increasing among HIV-infected persons.
T he incidence of genital human papillomavirus (HPV) infection is high, up to 7,440 per 100,000 person-years, in HIV-infected youth in the United States. 1 Although HPV infections often selfresolve, up to 69% of anal HPV persists after 2 years in men who have sex with men (MSM). 2 Persistent anal infection with high-risk HPV types increases the risk of anal squamous intraepithelial lesions (ASILs) in HIV-infected MSM. 3 Although HPV vaccination can reduce this risk 4 and has been recommended for boys since 2011, 5 vaccination completion rates remain poor. 6 Therefore, many HIV healthcare providers rely on secondary prevention of anal cancer with early detection and management of ASIL. 7 The epidemiology of cancer in HIV-infected persons has changed over time, with increased anal cancer incidence in the last 20 years. 8 HIV-infected MSM have the highest rates of invasive anal cancer (131 per 100,000 person-years), up to 3 times higher than other HIV-infected men (46 per 100,000 person-years), and 60-100 times higher than the general population (0-2 per 100,000 person-years). 8, 9 Although the data are limited, one study suggests that the rate of histologic ASIL is at least as high in HIV-infected male-to-female transgender women (transwomen) as it is in HIV-infected MSM at 91% and 84%, respectively. 10 There are no national guidelines for anal cancer screening, although experts recommend screening high-risk populations. 7 As a result, screening practices vary in age at initiation, type, and frequency. 7 One commonly adopted screening method includes detecting abnormalities via anal cytology and confirming the diagnosis with high-resolution anoscopy (HRA)-guided or intraoperative biopsy. 11 This process rarely begins before the age of 25 years in HIV-infected men. 12 In the southern United States, the rates of HIV and other sexually transmitted infections (STIs) are disproportionately high in young black MSM and transwomen. 13, 14 Our study aims to characterize the prevalence and severity of abnormal anal cytology and histology in HIV-infected young MSM and transwomen in Atlanta, Georgia. We also aim to determine the demographic, behavioral, and clinical factors associated with ASIL.
MATERIALS AND METHODS

Setting
This single-center, retrospective study was conducted at a publicly funded HIV clinic affiliated with a teaching hospital. The clinic is the primary referral center for HIV-infected youth in Atlanta, Georgia, and serves a diverse socioeconomic patient population. Informed consent was waived in accordance with institutional guidelines. Ethical approval for this study was obtained from the Emory University Institutional Review Board (IRB000-57152, 03/21/2019) and the Grady Memorial Hospital research oversight committee. with a male. Subjects were included if they were 13 to 24 years of age at the time anal cytology was first obtained and attended the clinic between January 2009 and December 2016. A transwoman was defined as a male-to-female transgender woman who was receiving hormonal therapy.
Procedures
Sexually active young MSM and transwomen had previously undergone screening per the process outlined in Figure 1 . Anal cytology samples were obtained by their regular HIV healthcare providers (medical doctors, physician assistants) according to the clinic's standard operating procedures and as previously described in the literature. 10 For those with abnormal cytology, the decision to repeat anal cytology or refer for diagnostic anal tissue biopsy by a surgeon or a specialist in HRA was made at the discretion of each provider. Samples for cytology and histology were evaluated by licensed clinical pathologists according to their standard operating procedures.
If an anal tissue sample was previously diagnosed as anal intraepithelial neoplasia 2 (AIN2) before the routine use of p16 staining, it was retrieved and re-examined using p16 for adjudication of the AIN2 diagnosis. 15 Per our local histopathology protocol, serial sections cut at 5 microns were taken from these formalin-fixed paraffin-embedded specimens and stained with hematoxylin and eosin. Adjacent samples were then stained with p16 (clone D25, MAB4133; Millipore Sigma, Billerica, MA) at a single laboratory (Winship Cancer Institute Pathology laboratory, Atlanta GA). A licensed pathologist and a senior pathology resident independently examined the specimens to determine the diagnosis according to the Lower Anogenital Squamous Terminology Standardization Project guidelines. 15 
Data Collection
Demographic, behavioral, and clinical exposure data were abstracted from medical records and analyzed. Demographics included age, race, education level, employment, housing, gender identity such as cisgender male or transwoman, and gender of sex partners such as men only or both men and women. Selfreported behavioral data included drug, alcohol, and tobacco use patterns; history and types of STIs; history of sexual abuse; participation in transactional sex, defined as the exchange of sex for payment or gifts, including but not limited to prostitution; type of anal intercourse defined as receptive, insertive, or both; and age at coitarche and lifetime number of sex partners of any gender. Information that was documented closest to the time of anal cytology was used for analysis.
As standard of care, clinic healthcare providers offered the HPV vaccine to all subjects 18 years or younger through the Centers for Disease Control and Prevention Vaccines for Children program. Subjects between the ages of 19 and 24 years were ineligible to receive the HPV vaccine free of charge in the clinic but could complete the series at their local health department. Human papillomavirus vaccination status at or before the time anal cytology was obtained was abstracted from the medical and state immunization records. Other clinical data included the presence or absence of anal condylomata (warts) on physical examination, CD4+ T-cell counts (CD4) and HIV quantitative RNA PCR or viral load (VL) at the time of HIV diagnosis (baseline), the first valid anal cytology test result, i.e., quantity and quality of specimen obtained was sufficient for analysis, and anal histology result. An undetectable VL (viral suppression) was defined as less than 40 copies/mL.
The primary outcome of interest was ASIL as identified on histology: negative, histologic low-grade squamous intraepithelial 
Statistical Analysis
Statistical analyses were performed using SAS v9.4 (Cary, NC). Significance was evaluated two-sided at the 0.05 level. Demographic, behavioral, and clinical characteristics were summarized using means and standard deviations, medians and interquartile ranges (IQRs), or frequencies and percentages. One-way analysis of variance (ANOVA) and χ 2 tests of independence were employed to evaluate bivariate associations and identify risk factors between categories of squamous intraepithelial lesion on anal histology and cytology. For data with nonnormal distribution or low frequency counts, we used nonparametric equivalents (Kruskal-Wallis and Fisher's exact tests, respectively). For clinical CD4 and VL variables, differences between categories of squamous intraepithelial lesion on anal histology and cytology were considered continuously using one-way ANOVA after square root transformation for CD4 and nominally for HIV suppression (VL <40 vs. VL ≥40) using χ 2 tests of independence. Interaction between categories of squamous intraepithelial lesion on anal histology and cytology for CD4 was assessed using two-way ANOVA. Unadjusted, pairwise post hoc tests were reported whenever omnibus tests were significant. Cohen's d effect sizes were interpreted as small (≥0.2), moderate (≥0.5), and large (≥0.8), hereafter referred to as d. Table 1 delineates the baseline characteristics of our study population. Ninety-five percent identified as African American. Among 314 subjects, the majority (99%) acquired HIV through sexual transmission. Most (98%) identified as cisgender male. We did not conduct a separate analysis to evaluate for unique risk factors in transwomen because of the low number of subjects, 7 (2%), in that group. Gender of sex partner was categorized as men only (76%) or men and women (24%). Drug use was frequently documented in our study population with marijuana use reported in 60% and tobacco use in 56%. Other illicit drug use was reported in 14% of subjects and included cocaine, methamphetamines (meth, ecstasy or molly), benzodiazepines, and lysergic acid diethylamide (LSD or acid).
RESULTS
Baseline Characteristics
Behavioral data were incomplete because of the retrospective nature of the study design. However, sexual abuse or transactional sex histories were documented in 33% (75/229) and 20% (35/179), respectively, of those with data. Of the 266 subjects who had a documented number of lifetime sexual partners, 41% had more than 20 partners. For those with reported data, the mean age at coitarche was 14.5 years (standard deviation (SD) = 3.3 years), and 9% (23/246) reported coitarche before the age of 9 years. Most subjects (87%) had a history of any STI, whereas 51% (153/303) had a history of rectal STIs, including herpes simplex virus, gonorrhea, chlamydia, lymphogranuloma venereum, and/ or trichomonas. Examiners identified external anal warts in 45% (130/288) of subjects with data.
Almost 90% (272/314) of subjects had no documentation of HPV vaccine receipt, whereas 5% were identified as having completed the 3-dose vaccine series. As documented by their healthcare providers, subjects identified the following barriers to HPV vaccine completion: HIV diagnosis and entry into care after the age of 18 years with ineligibility for the Vaccines for Children program, long wait times at the health department, and high cost of the HPV vaccine for persons without health insurance. Prevalence and Risk Factors for Abnormal Anal Cytology Figure 1 outlines the process for anal cancer screening in our clinic. Of note, 314 subjects met inclusion criteria, and 267 of those had been screened with anal cytology. Providers obtained anal cytology more frequently from subjects who practiced any receptive anal intercourse (86%) than from those who reported exclusive insertive intercourse (58%). Two hundred forty-nine (93%) specimens with a valid result were obtained from screened subjects. The mean age at anal cytology testing was 20.7 years (SD = 2 years, range 15-24 years).
Very few subjects (5%) had negative cytology tests. Most had cLSIL (43%) or ASCUS (41%) see (Table 2 ). Our analysis of the association between demographic, behavioral, and clinical factors and cytology results is displayed in Table 3 Specifically, there were significant pairwise differences in CD4s between ASC-H/HSIL and negative group samples and in the LSIL group relative to those with ASCUS and negative cytology. A large proportion of subjects who were screened with cytology, 48% (116/240), had documented anal warts. Those with cLSIL were more likely to have anal warts than subjects with ASC-H/cHSIL and ASCUS cytology. The proportion of subjects with an undetectable VL at the time of anal cytology was not associated with the degree of cytologic ASIL (χ 2 = 3.64, p = .303).
Prevalence and Risk Factors for Abnormal Anal Histology
Our analysis of the association between demographic, behavioral, and clinical factors and anal histology is displayed in Table 4 . The mean age at biopsy was 22 years (SD = 2.11 years, range = 17-26 years). Whereas 92% of those referred for surgical examination under anesthesia presented for biopsies, only 28% of those referred for HRA presented for the procedure. Seventy-two subjects underwent confirmatory diagnostic testing with either intraoperative or HRA-guided anal tissue biopsy. The majority of those (58%) had hHSIL including carcinoma in situ (CIS), whereas the remainder had hLSIL-AIN1 (28%) or were negative (14%) see (Table 2 ). Of note, the two subjects with hHSIL-CIS were diagnosed at the ages of 20 and 23 years. One subject with negative histology had been referred for surgical removal of anal warts without preliminary cytologic screening. Subjects reporting more sexual partners (≥21) exhibited a significantly higher degree of ASIL (Fisher TP < 0.001, p = .017, d = 1.3). Most subjects, 60 (83%), had anal warts at the time of biopsy. There was no association between presence of external anal warts and findings on histology (Fisher TP = 0.074, p = .737).
DISCUSSION
To our knowledge, this study is the first to investigate the prevalence and associations of ASIL in this age group using a combined cytologic and histologic approach. Previous studies in adolescents and/or young adult MSM have focused on cytologic abnormalities or HPV infection without confirmed histologic ASIL and, in all but one, have excluded persons with HIV infection. [16] [17] [18] [19] Our study population, young African American MSM and transwomen, represent the demographic groups most affected by HIV in the Southeast United States at this time. 13, 14 In our study, most (95%) of those screened had detectable cytologic ASIL. This was significantly higher than the prevalence of abnormal anal cytology (53%) in another urban population of HIV-infected young adult MSM aged 17 to 25 years (mean age = 21.2 years) 19 and in HIV-infected adult MSM (47%-62%). 20, 21 Furthermore, the type of abnormal cytology was more heavily skewed toward cLSIL and ASC-H in our population (43% and 9%, respectively). These results were more consistent with those seen in HIV-infected adult MSM (cLSIL = 54%, ASC-H = 6%) 20 than in the other study population of young adults (cLSIL = 28%, ASC-H = 3%) despite the slightly younger mean age of our subjects. 19 There is less known about the prevalence of ASIL in HIV-infected transwomen, particularly in the younger age group. However, in 1 study of HIVinfected adult transwomen, abnormal anal cytology rates were similar to those seen in MSM (cLSIL = 36%, cHSIL = 14%, ASC-H = 5%). 10 Most of our subjects who underwent biopsy (58%) had hHSIL see (Table 2 ). This is similar to rates seen in adult HIV-infected transwomen (59%), 10 but higher than published rates of hHSIL (31%-52%) in adult HIV-infected MSM. [22] [23] [24] Whereas hHSIL often takes years to progress to anal cancer, 24 some have shown this progression in as few as 8 months 25 although these data may be limited because of diagnostic bias. At this time, it remains unclear what factors hasten progression to anal cancer. In our study, hHSIL was significantly associated with a high number (≥21) of lifetime sexual partners. Various behavioral factors such as participation in transactional sex, anonymous sex, and history of incarceration may explain why some young MSM and transwomen have high numbers of sex partners. 26 This study did not reveal additional behavioral or clinical associations with cHSIL or hHSIL that might be used for risk stratification, although current or prior tobacco use has been identified as a possible risk factor in older adults in some studies. 27, 28 Our study highlighted some of the challenges in relying solely on primary prevention with vaccination in these populations. The nonavalent HPV vaccine includes the most common high-risk HPV types in adult HIV-infected MSM. 29 Only 5% of our study population had documentation of completing the HPV vaccine series, although we could not account for those who may have received HPV vaccination without documentation in the state immunization record or medical chart. Of note, almost 10% of subjects with data had experienced coitarche before the age of 9 years when they would have become eligible to receive the vaccine. Therefore, these young MSM and transwomen are 30 This indicates that although there have been some improvements over the years, a significant portion of young MSM and transwomen will remain at risk for HPV infection and its potential complications until vaccination rates improve. Because of the large population of HIV-infected young MSM and transwomen that are at risk for ASIL and cancer, there is a need for a standardized, evidence-based screening process. Therefore, we propose that providers consider anal cancer screening in sexually active, HIV-infected young MSM and transwomen with multiple lifetime sexual partners in demographically similar populations in the southeast United States starting at the age of 21 years, regardless of history of receptive anal intercourse, anal warts, or viral load.
This study was subject to several limitations. The primary goal of this study was to explore the associations of various exposures with ASIL outcomes, and thus, we had relatively small sample sizes. As such, post hoc tests were presented and interpreted unadjusted. In addition, there was variation in cytologic screening based on sexual practices and presence of anal warts on visual examination within our clinic, and our loss to follow-up rate for HRA was high. The reasons for poor adherence to the management plan were likely multifactorial with adolescent behavior, availability of trained providers, and lack of standardized management guidelines with resultant variability of provider practices among the most important. Implementing a standardized process for anal cancer screening with scheduled reminders for follow-up would address this limitation. This would allow us to better estimate the prevalence of ASIL in this population and overcome selection bias to produce recommendations that could be generalized to broader populations. Our analyses of disease risk were also limited by information bias due to the retrospective study design because some behavioral variables were inconsistently documented and may be important factors to consider in determining risk for hHSIL. Inconsistent documentation may have also contributed to our low immunization rates. Future prospective, multisite studies with standardized risk-assessment tools and biological analyses of those persons with CIS and other hHSIL would help identify viral and/or host factors that may affect regression of dysplastic lesions or progression to cancer. In addition, dedicated research in transwomen will be important to elucidate the role of hormonal therapy in disease progression.
CONCLUSIONS
Our study population of HIV-infected young MSM and transwomen demonstrated a high prevalence of high-grade squamous intraepithelial lesions, particularly in subjects with high numbers of sexual partners. This highlights the value of early, standardized anal cancer screening and active surveillance in similar high-risk, unvaccinated, and undervaccinated populations to decrease future risk of anal cancer.
